Download Free Sample Report

The global Bispecific Antibodies for Cancer market was valued at US$ 1.8 billion in 2023 and is projected to reach US$ 17.4 billion by 2030, at a CAGR of 36.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report studies the Bispecific Antibodies for Cancer market, covering market size for segment by type (CD19/CD3, CD30/CD16A, etc.), by application (Hematological Cancers, Solid Tumors, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Amgen, Immunocore, Roche, Astella Pharma, Merus, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).

This report provides detailed historical analysis of global market for Bispecific Antibodies for Cancer from 2018-2023, and provides extensive market forecasts from 2024-2032 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Bispecific Antibodies for Cancer market.

Leading Players of Bispecific Antibodies for Cancer including:

• Amgen
• Immunocore
• Roche
• Astella Pharma
• Merus
• Regeneron Pharmaceuticals

...

Market split by Type:

• CD19/CD3
• CD30/CD16A

Market split by Application:

• Hematological Cancers
• Solid Tumors
• Others

Market split by Sales Channel:

• Direct Channel
• Distribution Channel

Market split by Region/Country:

• North America (United States and Canada)
• Europe (Germany, UK, France, Italy, Spain, and Russia, etc.)
• Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia, etc.)
• South America (Brazil, Mexico, and Argentina, etc.)
• Middle East & Africa (Turkey, UAE, Saudi Arabia, and South Africa, etc.)

If you have any special requirements, please let us know and we can provide you the customized report as you want.